Tenaya Therapeutics (TNYA) Accumulated Expenses (2020 - 2026)

Tenaya Therapeutics' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $6.0 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 4.19% year-over-year to $6.0 million; the TTM figure through Mar 2026 stood at $6.0 million (down 4.19% YoY), while the FY2025 annual figure was $8.8 million, up 9.96% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $6.0 million, down from $8.8 million in the prior quarter.
• The five-year high for Accumulated Expenses was $12.8 million in Q4 2023, with the low at $6.0 million in Q1 2026.
• The 5-year median for Accumulated Expenses is $8.4 million (2022), against an average of $8.5 million.
• The sharpest annual moves came in 2022 and 2024: Accumulated Expenses soared 202.2% in 2022, then tumbled 37.15% in 2024.
• Tenaya Therapeutics' Accumulated Expenses stood at $10.7 million in 2022, then advanced by 19.88% to $12.8 million in 2023, then sank by 37.15% to $8.0 million in 2024, then gained by 9.96% to $8.8 million in 2025, then sank by 31.75% to $6.0 million in 2026.
• Business Quant data shows TNYA's Accumulated Expenses at $6.0 million in Q1 2026, $8.8 million in Q4 2025, and $7.4 million in Q3 2025.